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Development of an Assay for a Biomarker
of Pregnancy and Early Fetal Loss
by R. E. Canfield,* J. F. O'Connor,* S. Birken,*
A. Krichevsky,* and A. J. Wilcoxt
Human chorionic gonadotropin (hCG) is a glycoprotein hormone, secreted by the syncytiotrophoblast
cells ofthe fertilized ovum, that enters the maternal circulation at the time ofendometrial implantation.
It is composed of two nonidentical subunits; a and 1, with molecular weights of 14 kD and 23 kD,
respectively. Its a subunit is identical in primary structure to its glycoprotein homologs, luteinizing
hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Human
chorionic gonadotropin binds to the same receptor as hLH and displays the same biological response,
namely, to stimulate the declining function ofthe corpus luteum to produce progestins and estrogen late
in the menstrual cycle. The differences in the structures ofhCG and hLH have been exploited to develop
antibodies that can measure hCG specifically in the presence of hLH.
Two-site antibody binding assays have been developed, based on a surface immunological concept of
hCG epitopes, that involve fourdistinct regions to which antibodies against hCG can bind simultaneously.
Antibodycooperativeeffects, inconjunctionwithkineticadvantagesderivedfromtheconcentrationfactors
by use ofthe sandwich assay technique (immunoradiometric assay, IRMA), have enabled development of
extremely sensitive and specific measurement protocols for urinary hCG. The assay described herein
permits the detection of pregnancy on an average 25.4 days after the first day of the preceding menses,
as opposed to 29.5 days forconventional radioimmunoassay techniques. In addition, the greater sensitivity
and specificity of this assay method has permitted the detection of episodes of fetal loss not detected by
radioimmunoassay ofurine specimens. A large scale epidemiological study is in progress using this assay
technique as a way to identify pregnancies that are lost before becoming clinically apparent. This meth-
odology provides a valuable tool for the determination of the rate of early fetal loss.
Introduction
Human chorionic gonadotropin (hCG) is a glycopro-
tein hormone that is secreted by the syncytiotropho-
blast and appears to enter the maternal circulation at
the time of endometrial implantation of the fertilized
ovum(1). Itsprincipalknownroleis toact attheovarian
corpus luteum to stimulate further the secretion ofpro-
gestins in support of the growth of the endometrium.
Its level in blood and in urine rises rapidly to reach a
maximum approximately 12 weeks after the onset of
the last menstrual period; thereafter, it slowly declines
until the fetus and placenta are delivered.
This paperdescribes the developmentandapplication
of an assay for this biomarker that can be used in field
studies of clinically inapparent, early fetal losses. The
text has been designed to provide those interested in
such epidemiologic studies with a brief review of the
chemistry andimmunochemistry thatled to anewassay
for this hormone; knowledge of these features is gen-
erally essential to improvement in assay design.
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Early Assays of the Pregnancy
Hormone, Human Chorionic
Gonadotropin (hCG)
IthasbeenknownforsometimethathCG, incontrast
to many other plasma proteins, is excreted in the urine
at a concentration that is approximately equal to that
in blood. The studies by Marshall et al. (2) showed this
tobethecaseforindividualsthroughoutthefirsttrimes-
ter, and more recent studies have documented that the
same relationship appears to exist even when minute
quantities of hCG are circulating in blood (3). Thus,
urine specimens have always been a ready source for
both assay and purification ofthis hormone. However,
it is likely that urine specimens also contain partially
degraded hormone fragments and measurement of a
serum specimen has sometimes been preferred for di-
agnostic interpretation.
Biological assays for hCG were first developed by
Aschheim and Zondek in the late 1920s (the A-Z test)
as a method to detect pregnancy several weeks after
the first missed menstrual period (4). In the 1960s im-
munologic assays for hCG began to replace the more
cumbersome bioassays (5,6). These also had the featureCANFIELD ET AL.
of increased sensitivity and reproducibility, leading to
earlier diagnoses ofpregnancy (7). However, polyclonal
(usually rabbit) antibodies raised against hCG always
cross-reacted to some extentwiththehumanluteinizing
hormone (hLH) in the maternal circulation or with this
hormone's components in urine. This is due to the con-
siderable degree of homology between hCG and hLH.
Thus, sensitivity ofthese assays forthe early detection
ofpregnancy was limited by the inevitable presence of
hLH immunoreactivity in maternal serum and also by
eithertheintacthLHhormoneoritsfragmentsinurine.
In the early 1970s the relationship of all the homol-
ogous glycoprotein hormonesbecame apparent withthe
discovery that each was composed ofa single ao subunit
and a single 13 subunit (8). While the amino acid se-
quences ofthe a subunits ofhLH and hCG were shown
to be identical, there were minor differences in the
structures of the 13 subunits as illustrated in the next
section (9-19). Vaitukaitis, Braunstein, and Ross found
that occasionally, a rabbit, when immunized with the
purified 1 subunit of hCG, made antibodies that were
predominantly directed against this hormone and had
limited cross-reactivity with hLH (20). This led to the
development ofradioimmunoassaysthatcouldroutinely
detect 1 ng/mL of hCG in serum in the presence of
circulating hLH. Radioimmunoassays with urine spec-
imens were more complex because of interfering sub-
stances andthepresence ofdegradationproducts. Many
manufacturers ofdiagnostic kits took advantage ofthis
assaymethodology, however, anddeveloped home test-
ing kits for hCG in urine specimens that could detect
pregnancywithmoderatereliability(21)duringthefirst
9 days after the first missed menstrual period.
Two developments opened the way for new hCG as-
says with enhanced sensitivity and specificity. One was
the production of monoclonal antibodies against the
hCG-1 subunit so that urine could be extracted effi-
ciently by immunoaffinity adsorption. The second de-
velopment was the finding that preparations of the
unique 13-COOH-terminal peptide region of hCG could
be employed asimmunogens to make high-affinity poly-
clonal antibodies (22). These are summarlzed in the fol-
lowing section.
The Chemistry and
Immunochemistry of hCG: Similarity
to hLH
Structural Considerations
The amino acid sequences of the glycoprotein hor-
mones thyroid-stimulating hormone (TSH), follicle-
stimulating hormone (FSH), luteinizing hormone (LH),
and chorionic gonadotropin (CG), all closely resemble
each other and probably evolved from a common an-
cestral gene (17,23). Each is composed of two noni-
dentical subunits, designated a and 1. In the human
there is only one gene for the a subunit (9), so all ofthe
hormones have the identical a subunit amino acid se-
quence, althoughcarbohydratedifferencesexist(15,17).
Hence, the structures ofthe 13 subunits are responsible
for the different target organ specificities, and these
have been shown to induce different conformational al-
terations when combined with their complementary a
subunits (24-26).
hLH and hCG act at the same receptor. hLH is se-
creted by the pituitary in a cyclic fashion during the
female reproductive years, with a pulsatile surge in
blood level just preceding ovulation, while hCG is the
chemical message secreted by the fertilized ovum for
the purpose of rescue of the corpus luteum from its
declining phase, just prior to menstruation. This latter
action serves to sustain a favorable endometrial envi-
ronment for the implanted, fertilized ovum. hCG and
hLH have very similar receptors specifying 13 subunits
whose structural similarities have been preserved dur-
ing evolution. The amino acid sequences ofthese 13 sub-
units, that have been derived from both protein chem-
ical and genetic analyses (9,11,27), are shown in Figure
1. The high degree ofhomology for the first 113 amino
acids, especially the alignment of the 12 half-cystine
residues, reflects their nearly identical receptor-speci-
fying structures. The pairing ofthe disulfide bridges is
still not definitively proven, although two bonds appear
firmly established for each subunit (17).
The location and structures ofthe carbohydrate por-
tions of hCG have been defined (Fig. 2). The carbohy-
drate structures ofhLH differfromthose ofhCGinthat
hLH contains a significant amount of sulfate-terminat-
ing sugar moieties as compared to the terminal sialic-
acid groups present in hCG (28,29). The carbohydrate
heterogeneity of the hCG-1-COOH-terminal region is
also ofinterest (30), although this area ofthe molecule
is probably more related to the prolonged circulating
half-life of hCG, as compared to hLH, and not to hor-
mone action at the receptor.
The studies by Fiddes et al. (31) suggest that an ev-
olutionary accident occurred at the terminator codon
for the 13 subunit of hCG, permitting the addition of
approximately 30 amino acids to that structure, which
are not present in hLH 13. This so-called 13-COOH-ter-
minal peptide region (13-CTP) of hCG thus provides a
unique epitope by which immunochemical recognition
of hCG can be achieved with absolute specificity, i.e.,
the 13-CTP structure does not exist in hLH.
Immunochemical Considerations
Our group and many others have raised preparations
of antibodies that recognize hCG and hLH to varyng
degrees (32). Ofparticular interest with regard to the
topic discussed here are those antibodies which exhibit
ahigh degree ofselectivity forhCG, i.e., have very low
reactivitywith hLH. Thefollowingdiscussionprimarily
outlines results from our own research group, but the
reader will also be referred to other studies that have
yielded comparable results.
Figure 3 depicts the a and 1 subunits ofhCG. In this
figurewe have defined fourregions, shownbythecross-
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FIGURE 1. Theamino acid sequence ofthe subunit ofhCG (10-12) ascompared tothatofhLH; thelatter wasdeterminedbyDNAsequencing
(27). The hLH sequence has over 80%o homology to hCG-,B, being different mainly in the COOH-terminal portion of each hormone. Car-
bohydrate groups are indicated by (CHO) above the amino acid to which it is attached.
hatched circles, that appear to give rise to antibodies
that can have a high degree of selectivity for hCG in
relation to hLH, i.e., they must have epitopes that re-
flect some ofthe differences in structure that are shown
in Figure 1. The following is a briefdescription ofeach
ofthe four regions shown in Figure 3.
Region I consists ofthe ,-CTP ofhCG. This has been
isolated, coupled to carrier proteins for immunization,
and shown togive rise to rabbit antibodies that are both
sensitive and specific for this structure (22). While the
binding constants of antibodies raised against the syn-
thetic peptide from this region have generally been low
(33), we have found that the presence of the carbohy-
drate side-chains on this peptide immunogen can give
rise to antibodies with considerable sensitivity and even
carbohydrate selectivity (22,34). These antibodies are
absolutely specific for hCG, since they are directed to
a structure absent in hLH (34). Interestingly, this re-
gion appears to be equally reactive in the native hor-
mone, in the free subunit, and in the reduced and
alkylated , subunit, suggesting that it is a structure
that is loosely arranged at the surface of the hornone
molecule and that the antibody combining sites recog-
nize elements of primary structure. Chen, Matsuura,
and colleagues have studied this phenomenon exten-
sively and suggest that most of the antibodies bind to
the last 15 COOH-terminal residues (35,36). Since the
onlyantibodiesthat wehave everobtainedtothisregion
with high affinities were polyclonal antisera raised in
rabbits, theexample shown is an antiserumfrom rabbit
hCG 0
hLH JO
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FIGURE 2. The structure ofthe carbohydrate moieties hCG-,B. Up-
perportionoffigure:N-asparagine-linked structures, showinghet-
erogeneity in the biantennary structures. Lower portion offigure:
the 0-serine-linked carbohydrate moieties present on the 1-CTP
portion of hCG-1. Recent studies have demonstrated the heter-
ogeneity in 0-serine-linked oligosaccharides (30).
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FIGURE 3. A schematic illustration ofthe orientation ofepitope ori-
entation in hCG. Determined as described in the text by competi-
tive binding studies with monoclonal antibodies. Four sites are
shown, based on the ability of antibodies to bind simultaneously:
site I, the ,BCTP region; site II, a conformationally dependent
region equally reactive with free 1B subunit and intact hCG; site
III requires combination of a and 1B subunits for binding, as ex-
emplified by human anti-hCG antibody H (39); site IV, the free 1B
subunit and fragment binding site.
525 (R525). Recently, Bellet and his associates (37), as
well as Stevens and colleagues (38), have obtained
monoclonal antibodies to this region.
Region II appears to contain the epitope for the an-
tibody developed by Vaitukaitis, Braunstein, and Ross
that was designated SB6 (20). Other monoclonal anti-
bodies listed in the figure as recognizing some elements
of this general region have been defined by virtue of
theirability to compete witheach otherforbinding(32).
In addition, they all have the characteristics ofbinding
relativelywelltothe I subunit, aswellastointacthCG,
and each requires that the P subunit be folded in its
native conformation for antibody binding.
Region III first became apparent to us when we had
the opportunity to study some human autoantibodies to
hCG and discovered that they reacted only with the
intact hormone, exhibiting virtually no reactivity for
either the isolated a or P subunits (39). This was a
distinct contrast to the antibodies of region II. Subse-
quently, we have discovered several monoclonal anti-
bodies (B107 and B109), which were raised against hCG
and exhibit similar properties of recognizing only the
intacthormone. These also compete forreactivityatthe
same site as the human antiserum. Monoclonal antibody
B101 has been assigned to this site, because it also com-
petes for binding with some of the antibodies shown
there (40).
Region IV represents an epitope that is not readily
reactive in native hCG but is present on the free ,
subunit and also on forms of the degraded hCG-,B sub-
unit that are excreted in human urine. For this reason
we suspect that it is covered in the native hormone by
the a subunit and have located it as shown in Figure 3.
Thisistheregionthathasbeenmostrecentlyidentified,
and it affords the opportunity to distinguish between
degraded hCG-,B subunit fragments and the intact hor-
mone. We have determined the complete structure of
the degraded 3-core fragment and have developed mon-
oclonal antibodies that bind to region IV (41,42).
Taken together, these results indicate that it is pos-
sible to define four separate regions in hCG that can
give rise to antibodies which maybe employedin assays
that will have a selectivity for hCG over hLH. Each of
these regions presumably reflects a structural change
resulting from amino acid differences shown in Figure
1. Several other research groups have also developed
epitopemaps ofhCG. Forexample, Schwartzetal. have
published a three-dimensional epitope map that was
producedbypermutationsofsimultaneousbindingstud-
ies of231 monoclonal antibodies (43). Bellet's group has
also published an epitope map of the P-CTP-terminal
region (44).
These details have been presented here largely to
define the nature of some of the reagents available for
the assay of this biomarker. One additional point un-
derscores the importance ofthese four discrete regions
ofthe hCG molecule. Immunoradiometric assays (sand-
wich assays) use two antibodies selected on the basis of
binding to different hCG epitope regions such as those
shown in Figure 3. In an early study it was found that
one such assay exhibited an affinity far beyond that
expected on the basis ofindividual antibodies. A math-
ematical model was developed (45,46) that accounts for
this observation by the prediction ofthe formation of a
circular complex composed of one molecule of each an-
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tibody and two molecules of antigen. Data illustrating
theseenhanced affinities arepresentedinFigure4. Fig-
ure 5 depicts the concept of this high-affinity circular
complex.
Development of a New Assay for
hCG
Given access to the immunochemical reagents just
described, it became possible to devise better assays
for hCG. We chose urine specimens for measurement
because they were easily collected in field studies; sav-
ingthefirstmorningvoided specimen seemedmuch less
cumbersomethanattemptingtoobtaina24-hrcollection
(47). Ifthis was to be the design, we next required an
antibody to extract (i.e., concentrate) the hCG from
urine by immunoaffinity adsorption. Monoclonal anti-
body B101 was ourfirst ,3-specific antibodythat became
available, so we chose it as the capture antibody. B101
was coupled to Sepharose beads so that hCG could be
bound to the immobilized antibody in a suspension of
urine and then removed by centrifugation to form a
pellet. This pellet, with the extracted hCGbound tothe
Fc | | Antibody
IIB 102
F(ab) F(ab)
hCG
F(ab) F(ab)
Fc Antibody
B I OI
A
B102 *
I I I liI l IJ J I
10-11 1610° lo9 10-e lo(7
hCG, (M)
B c
.8 r-.
.6- .6 _
,2 X. .2
- 0
4 8 12 16 0 4 8 12
BOUND x 10-" BOUND x Q10-'
D
A
.3 0
.2
.1 \
0\
., i, ., \
0 4 8 12 16
BOUND x 10-9
FIGURE 4. Antibody affinity enhancement due to circular complex
formation. This figure shows cooperative effect that occurs when
two antibodies that bind to different sites form a circular complex
resulting in an affinity to hCG higher than that ofeither antibody
alone. (A)the increase insensitivityformeasurement ofhCGwhen
two antibodies are mixed; (B) the estimated affinities of the an-
tibodies alone or in the mixture. The data in (A) were obtained
by radioimmunoassay for hCG using the double-antibody liquid-
phase assay with antibodies B101, B102, and a mixture of B101
and B102. The amounts of labeled hCG bound in the absence of
unlabeled inhibitor was approximately the same for each antibody
or antibody mixture. Rabbit anti-mouse IgG was the second an-
tibody. The Scatchard analysis ofthe binding ofhCG to a mixture
of antibodies B101 and B102 (B), antibody B101 alone (C), and
antibody B102 (D) yielded values for the equilibrium binding con-
stant of 5.4 x 109 for (B); 5.1 x 108 for (C); and 1.9 x 107 for
(D). Reproduced from (61).
FIGURE 5. Circularcomplexformation. This diagram shows the cir-
cular molecular complex that is proposed as responsible for the
affinity enhancement observed in some mixtures of monoclonal
antibodies. Two monoclonal antibodies that bind to two distinct
sites on hCG are capable of forming a complex as shown, which
is composed of the two different antibodies molecules and two
molecules ofhCG (46).
antibody, could then be washed and recentrifuged sev-
eral times to remove any nonspecific, interfering sub-
stances, or proteolytic enzymes. Since antibodies tothe
3-CTP region were absolutely specific for hCG, we
elected to purify the rabbit IgG to that region (R525)
and radiolabeled it with 125I as the measuringantibody.
In other words, when this measuring antibody was in-
cubated with the washed pellet, obtained from a Se-
pharose-B101-hCG suspension, the higher level of ra-
dioactivity bound to the solid phase, the greater the
quantity ofhCG attached to the capture antibody. The
scheme for this immunoradiometric assay (IRMA) is
shown in Figure 6A, and a standard curve for such an
assayisillustratedinFigure6B. ItcanbeseeninFigure
6B that the hLH preparation (,ug/mL) reacts less than
one part in 10,000 withhCG (ng/mL). We do notbelieve
that this is cross-reactivity between the two, rather it
represents the minute quantities ofhCGthat have been
reported in human pituitary preparations (48-51) co-
purified with hLH.
It can be seen from Figure 6B that this assay design
permitted hCG detection at concentrations approaching
0.01 ng/mL, which was 50 to 100 times more sensitive
than any other existing assay methodology.
Next we needed an indication that these low urinary
concentrations actually reflected blood levels ofthe hor-
mone (Fig. 7A) and also to apply the assay to a variety
of normal individuals (Fig. 7B). Indeed, the decline of
hCG
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FIGURE 6. Design oftheimmunoradiometric assay (IRMA) forhCG
and standard curve illustrations. (A) The hormone is first ex-
tracted from urine with inmnobilized monoclonal antibody B101,
specific for region III. The immobilized antibody-antigen complex
is washed free ofinterfering substances and then incubated with
the radiolabeled 13-COOH-terminal specific antibody R525. After
washing and centrifugation to remove unbound trace, the "sand-
wich" is counted in a gamma counter. The quantity of radiolabel
present is directly proportional to the amount of antigen (hCG)
present in the sample. (B) Measurement ofhCG and hLH in urine
by the IRMA. Urine is shown not to interfere with measurement
ofhCG. hLH is shown to cross-react less than one part in 10,000.
IRMA of hCG added to buffer (0) and to urine (A) of a normal
man; hLH added at high concentration to urine (A) of a normal
man. The units ofconcentration for hCG and hLH are ng/mL and
,ug/mL, respectively. Reproduced from (3).
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FIGURE 7. UrinaryhCG assayresultsfromnormalhuman subjects.
(A) hCG excretion rate for a man injected with 3000 IU of hCG
for treatment ofinfertility. Daily first morning voided urine spec-
imens were collected, and the concentration ofhCG in ng/mg cre-
atinine were determined by IRMA. The half-life of hCG was 29
hr. (B) Values for ng hCG/mg creatinine obtained by IRMA of
urine specimens from normal men and normal premenopausal and
menopausal women. The arrows indicate the mean values and the
brackets represent ± 1 SD of the means for detectable levels in
each group. Reproduced from (3).
hormone in urine in men who had received a single
injection of hCG follows the expected decline in blood
levels. While men and women ofreproductive age gen-
erally had undetectable or extremely low levels of uri-
nary hCG, we found that menopausal females did have
detectable quantities covering aratherwide range. This
has also been noted by others (48,49) and probably rep-
resents the effect of ovarian failure in the menopause
leading to a profound stimulus for excess gonadotropin
secretion that includes a small fraction ofhCG.
Field Studies of Early Fetal Loss:
Testing the Utility of the hCG Assay
Thus far we have described how biochemical and im-
munochemical information has been used to devise a
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new, sensitive assay for hCG in urine specimens, but
its applicability as a biomarker for early fetal loss in
epidemiologic studies required evaluation. To demon-
strate the applicability of hCG as a biomarker, a rela-
tively small trial was conducted to ascertain whether
the design of the study was feasible and whether new
assays for hCG in urine, with enhanced sensitivity,
would yield new data. Specimens were also analyzed by
the method employed by an earlier investigator (53).
The field studies enrolled women as paid volunteers.
Each woman collected approximately 1 ounce of urine
eachmorningandstoredthecontainersfrozenuntilthey
were picked up for assay. Details of the study design
have been described elsewhere (47). To date, we have
completed three studies testing the utility of these as-
says. In the first, 30 women collected daily urine spec-
imens from the time they stopped contraception until
theybecamepregnant, orforsixmonthsifnopregnancy
occurred (47). This study notonlyshowedthefeasibility
of the epidemiologic design, but it also permitted the
detection of several cycles with early fetal loss that
would not have been detected by any other available
methodologies. This preliminary study is the basis for
a larger study currently in progress, which will more
accurately define the incidence ofsuch clinically unrec-
ognized early fetal loss.
A second study group was composed of women who
had undergone tubal ligation; no patterns suggestive of
pregnancy have been seen so far. In the third group,
women who were using intrauterine devices as a means
of contraception were evaluated to determine whether
this contraceptive technique prevented implantation of
the fertilized ovum. Urinary hCG was-detected in only
1 of 107 menstrual cycles in this study (54), indicating
that implantation is an infrequent event among women
who use IUDs for contraceptive purposes. The assay
technique could not rule out the possibility that the
single pregnancy loss detected might have been a tubal
implantation.
Figure 8 has been reproduced (55) to illustrate the
type of findings that may be obtained in field studies.
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FIGURE 8. Menstrual cycle hCG values obtained by IRMA tech-
nique. Three consecutive menstrual cycles in which daily urines
were collected during the second half of the cycle. Assay of hCG
indicates that no conception occurred during the first cycle (hCG
< 0.01 ng/mL). During the second cycle, hCG values rose for 6
consecutive days (peak value of 0.38 ng/mL hCG) and then fell,
indicating a preclinical fetal loss. The third cycle indicates the
rising level ofhCG of a normal pregnancy. Reproduced from (55).
Threeconsecutivemenstrualcyclesofoneindividualare
illustrated in which urine specimens were collected
daily. During the firstcycle no conception occurred. All
hCG values were less than 0.01 ng/mL. During the sec-
ondcycle, 3weeksaftertheonsetofthepriormenstrual
period, urinary hCG rose for 6 days to 0.38 ng/mL.
Human chorionic gonadotropin steadily declined over
the next 6 days, returning to undetectable levels. With
the decline of hCG came the onset of menses, 27 days
after the onset ofthe previous menses. This individual
was unaware of her pregnancy or the episode of early
fetal loss. However, the finding of 11 consecutive ele-
vations of urinary hCG above the normal background
for this individual, in a pattern of rise and then fall,
leave little doubt that a loss has occurred. Three weeks
aftertheapparentfetalloss, thiswomanagainexhibited
a rising level of urinary hCG. This time she remained
pregnant and delivered a normnal, full-term infant.
One additional point should be added concerning the
advantage ofan immunoradiometric assay. When acon-
ventional radioimmunoassay is perfonned on a urine
specimen, contaminating proteolytic enzymes in the
urine may degrade the radiolabeled tracer during its
incubation. This proteolytic artifact may lead to falsely
elevated measurements of hCG. In addition, other in-
terfering urinary substances may add to background
baseline variations and decrease the signal-to-noise ra-
tio for detection of pregnancy. In the immunoradiome-
tric assay, the radioactive tracer is introduced after
proteases and interferingsubstances have been washed
away. For example, the SB-6 radioimmunoassay in
urine displays a poor signal-to-noise ratio with a wide
variation between 1 to 10 ngfmL (47). This contrasts
with the data from the immunoradiometric assay per-
formed on the same specimens which display greater
sensitivityfor hCGwithout thewidelyfluctuatingbase-
line (47). These factors may have contributed to the
differing results (8-57%) obtained in prior studies of
early fetal loss (56-58).
Rationale for Future Assay
Developments
As noted at the outset, tests for hCG have evolved
over the past 5 decades from crude bioassays to highly
sensitive and specific immunoassays. The hCGmolecule
is well-characterized and arelatively specific product of
pregnancy. Its ectopic secretion by some tumors and
its slight elevation in postmenopausal women (49-52)
do not lessen its epidemiologic value as a biomarker for
pregnancyin healthywomen ofreproductive age. Other
placental proteins that have been described as preg-
nancy-specific have proven to be ofless utility to detect
early pregnancy. Furthermore, these products are typ-
ically assayed in blood, and their fate in urine is less
well known (59).
The careful description of early pregnancy loss re-
quires not only a reliable assay but also frequent mea-
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surement. The collection ofdaily urine specimens from
women attempting pregnancyhas proventobefeasible.
Data from such studies show that hCG can be detected
within a few days ofthe expected date ofimplantation
and, on average, at least 2 days before the onset ofthe
expected next menses. Early fetal losses are detectable
with this approach, although an assay needs to be sen-
sitive and reliable to atleast0.05ng/mL ofhCGinorder
to detect most ofthese losses clearly.
Many research groups have contributed to advances
in the techniques for studying early pregnancy. Still
more remains to be done ifepidemiologic studies are to
be carried out efficiently. The best available methods
for measuring hCG are complex, time-consuming, and
expensive. We suggest here some specific and feasible
ways in which hCG assays might be refined.
New Monoclonal Antibodies for hCG
Detection
Although urinary hCG is predominantly in its intact
form, there are several forms of fragmentary hCG as
well, each with distinct immunochemical properties. In
ordertomeasure thecompleteurinaryproducts ofhCG,
new antibodies with high affinities forthe various prod-
ucts are needed. Ideally, these should be monoclonal
antibodies, in order to assure a continuous supply of
well-characterized reagents. The complete detection of
hCG in its various forms would maximize sensitivity
and assure that unusual events such as a decrease in
the secretion ofone ofthe subunits could be described.
Nonradioactive Methods for hCG
Detection
The use of radioactive iodine in immunoassays has
been highly successful, but not without disadvantages.
First, radiolabeled reagents must be freshly prepared
and characterized every few weeks and then shipped to
users. Second, the use of radioactive materials in the
laboratory requires special training and surveillance.
Third, there is an increasing problem with radioactive
waste disposal. The application of newer technologies
such as a fluorescent immunoassay would allow greater
ease and flexibility oflaboratory support for field stud-
ies.
Systematic Comparisons of hCG Assays
The suggestions above are aimedtowardmakinghCG
assays as accurate, rapid, and inexpensive as possible.
Such improvements would greatly increase the appli-
cability of such assays in epidemiologic studies. How-
ever, with every change in assay method, there is the
problem ofpotential noncomparability ofresults among
different assays. Every effort should be made to char-
acterize the properties ofnew assays in a way that will
allow the results of epidemiologic studies to be mean-
ingfully compared.
Related Research Opportunities
Urinary hCG is a useful marker for detecting the
fertilized ovum around the time of implantation. How-
ever, thismarkercannot detectearlierlossofthe ovum.
Possible methods for earlier detection of pregnancy
should be pursued (60).
In the broader context ofreproductive studies, there
is a need for continued progress in the development of
markers of ovarian function, including ovulation. As
with hCG, the most useful markers for epidemiologic
research are those detectable in easily collected biolog-
ical specimens such as urine or saliva. The pituitary
gonadotropins (hLH and hFSH) can be useful for de-
termining the timing of ovulation (1). The various es-
trogen and progesterone derivatives can be used to
identify ovulation as well as to measure the follicular
and luteal functions of the ovary. The same improve-
ments that were discussed for hCG assays would be
useful for assays ofthese hormones.
The measurement of reproductive dysfunction (with
early pregnancy loss as a specific example) may be use-
ful in studies ofenvironmental toxins. For such studies
ofearly loss to be reliable, more information about ma-
jor factors that affect such risk are needed. Does the
risk ofearly loss increase with the mother's age? Is risk
affected by the type of birth control previously used?
Is the risk associated with other types ofreproductive
failure, such as spontaneous abortion? Is the risk ofloss
a function of other events of the cycle, such as length
of the luteal phase or the timing of intercourse in re-
lation to ovulation?
There are clinical questions as well that can be ad-
dressedbystudies ofearlyfetalloss. Thesefocusmainly
on the possible contribution ofunrecognized loss to in-
fertility. Syndromes involving very early loss may be
so rare as to be unimportant to epidemiologic studies
of environmental hazards, but the syndromes are im-
portant nonetheless for diagnosis and treatment of in-
fertility. Allthesebasicquestions, whethercomingfrom
the epidemiologist or the clinician, are now answerable
with tools that were unavailable until recently. Work
will be further enhanced when more convenient assays
for hCG are available.
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